Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — Shareholder Meeting (March 2022)
26 slides from Nxera Pharma's shareholder meeting presentation, Mar 24, 2022
Slide 1: 32nd Ordinary General Meeting of Shareholders
NON – CONFIDENTIAL 32nd Ordinary General Meeting of Shareholders Sosei Group Corporation | 第32回定時株主総会 24 March 2022| 2022年3月24日
Slide 2: Agenda
Agenda 1 Opening Declaration 2 Report on number of voting rights 3 Audit Committee Report 4 FY2021 Results and Business Report 5 Report on Audit Results 6 Resolution 7 Q&A 8 Vote 9 Closing Declaration 1
Slide 3: Opening Declaration
1 開会宣言 Opening Declaration 2
Slide 4: Report on the number of voting rights
2 議決権個数のご報告 Report on the number of voting rights 3
Slide 5: Audit Committee Audit Report
3 監査委員会の監査報告 Audit Committee Audit Report 4
Slide 6: FY2021 Consolidated Results Business Report
4 2021年12月期の事業報告 連結業績 FY2021 Consolidated Results Business Report 5
Slide 7: Another year of successful execution
Another year of successful execution Summary Financial Highlights for the 12 months ended 31 December 2021 Revenue of ¥17,712m ($161m) vs. ¥8,842m ($83m) in prior year, substantial increase driven by 1 Neurocrine transaction. Core Earnings of ¥8,904m ($81m) vs. ¥2,904m ($27m) in prior year; Operatin
Slide 8: Cost Guidance for FY2022
Cost Guidance for FY2022 Guidance stated on total IFRS expenses basis going forward, rather than cash basis used in FY2021 R&D expenses (IFRS basis) G&A expenses (IFRS basis) ¥5,750 to 6,750m ¥3,750 to 4,250m (FY2021: Actual ¥5,931m) (FY2021: Actual ¥3,940m) • Expand platform and grow discovery • In
Slide 9: Achievement in FY2021
Achievement in FY2021 Promote future growth through both organic and strategic growth FY2021 OBJECTIVES ACHIEVEMENT Execute 2-3 new high value collaborations and/or 1 co-investments every year ✓ Completed: 1 Organic 2 Expand expertise in GPCRs ✓ Continue to update Completed: drug discovery platform
Slide 10: Major licensing deals
Major licensing deals Achieved one of the largest executed CNS license collaborations with Neurocrine in 2021 Upfront and Initial Potential Total Partner Execution Program Therapeutic Area Milestone Milestone1 Collaboration and license agreement November 2021 Neurological disorders $100m $2.6bn for
Slide 11: R&D to support faster, more efficient testing in the clinic
R&D to support faster, more efficient testing in the clinic Four programs prioritized to start over the next 24 months Schizophrenia Atopic Immunosuppression Inflammatory and Psychosis Dermatitis in solid tumours Bowel Disease GPR52 agonist H4 antagonist EP4 antagonist EP4 agonist TARGET PRODUCT PRO
Slide 12: Achievement in FY2021 (Organic Growth)
Achievement in FY2021 (Organic Growth) Major progress in muscarinic and drug discovery platform are in the following slides FY2021 OBJECTIVES ACHIEVEMENT Execute 2-3 new high value collaborations and/or 1 co-investments every year ✓ Completed: 1 Organic 2 Expand expertise in GPCRs ✓ Completed: Conti
Slide 13: M4 agonist competition landscape
M4 agonist competition landscape Muscarinic M4R now an increasingly de-risked and validated target for multiple types of SZ We are potentially best in class CVL-231 • Avoids non-M4R Lead Program KarXT HTL16878 muscarinic side (Emraclidine) effects Mechanism of M1/M4 agonist Action M2/M3 antagonist M
Slide 14: Our discovery platform updates
Our discovery platform updates Further strengthening our world leading platform for GPCR by developing new technology Pre-Disc. / Discovery Preclinical studies Clinical studies Commercialization Target ID Structure Hit ID Lead Optimization Solid Core StaR® SBDD Technologies (Stabilised Receptor) (St
Slide 15: Achievement in FY2021 (Strategic growth)
Achievement in FY2021 (Strategic growth) Major progress in new technologies and expansion beyond GPCR are in the following slides FY2021 OBJECTIVES ACHIEVEMENT Execute 2-3 new high value collaborations and/or 1 co-investments every year ✓ Completed: 1 Organic 2 Expand expertise in GPCRs ✓ Completed:
Slide 16: Strategic collaboration landscape
Strategic collaboration landscape Significant build of in-house methods and industry collaborations to drive new best practice Pre-Disc. / Discovery Preclinical studies Clinical studies Commercialization Target ID Structure Hit ID Lead Optimization Choosing the right target Our Core Technologies Sta
Slide 17: Overview for our growth strategy
Overview for our growth strategy Mid to long-term direction for accelerating our growth For our tech-based drug discovery platform (StaR®/SBDD) For our future strategic growth Increase the value of the deal by out-licensing Pivot to a program-centric focus, and build and after obtaining POC in y
Slide 18: Priority objectives for FY2022
Priority objectives for FY2022 Continue to promote future growth through both organic and strategic growth FY2022 OBJECTIVES Execute at least one new high value collaborations and/or 1 co-investments Organic Growth 2 Generate at least one new preclinical candidate 3 Further enhance platform producti
Slide 19: Priority objectives for FY2022 (cont'd)
Priority objectives for FY2022 (cont'd) Promote sustainable ESG practices and policies across global business Sustainable Development Goals adopted by the United Sosei Heptares is undertaking initiatives focused on Nations (Sep-15) 10 of the 17 Sustainable Development Goals E Environment S Social G
Slide 20: Report on Audit Results on the Consolidated Financial Statement
5 連結計算書類の監査結果報告 Report on Audit Results on the Consolidated Financial Statement 19
Slide 21: Matters to be Resolved
6 決議事項 Matters to be Resolved 20
Slide 22: Proposal No.1: Partial amendments to the Articles of Incorporation
Proposal No.1 Partial amendments to the Articles of Incorporation 19
Slide 23: Proposal No.2: Election of Eight Directors
Proposal No.2 Election of Eight (8) Directors Chairman of the Board, Representative Executive 1 Shinichi Tamura Officer, CEO, Chair of the Nomination Committee, RE-APPOINTED Member of the Compensation Committee 2 Christopher Cargill NEWLY Executive Officer, CFO APPOINTED External Director, Chair of
Slide 24: Q&A
7 質疑応答 Q&A 23
Slide 25: Vote
8 採決 Vote 24
Slide 26: Closing Declaration
9 閉会宣言 Closing Declaration 23